MedTrace Logo

Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses

NCT00110682 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-04-24

No results posted yet for this study

Summary

Study Aims:

* To compare the long-term efficacy and safety of imiquimod versus vehicle used as an adjunct to cryotherapy.
* To assess and compare the recurrence rate and time to recurrence of the 2 different treatment groups.

Hypothesis: The imiquimod arm will produce a more prolonged clearing of Actinic Keratoses (AK) compared to the vehicle arm.

Conditions

  • Keratosis
  • Actinic Keratosis

Interventions

DRUG

Imiquimod used as an adjunct to cryotherapy

Sponsors & Collaborators

  • 3M

    collaborator INDUSTRY

  • Derm Research @ 888 Inc.

    lead INDUSTRY

Principal Investigators

  • Yves Poulin, MD FRCPC · Centre de Recherche Dermatologique du Quebec Metropolitaine

  • Jerry KL Tan, MD FDRPC · U. of Western Ontario, Windsor Ontario

  • Richard Thomas, MD FRCPC · Derm Research @ 888 Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2006-10-31
Completion
2006-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00110682 on ClinicalTrials.gov